Eric B Suhler

Summary

Country: USA

Publications

  1. ncbi Presumed teratoma-associated paraneoplastic retinopathy
    Eric B Suhler
    Arch Ophthalmol 121:133-7. 2003
  2. ncbi HLA-B27-associated uveitis: overview and current perspectives
    Eric B Suhler
    Casey Eye Institute, Oregon Health and Science University, and Portland VA Medical Center, Ophthalmology Service, 97239, USA
    Curr Opin Ophthalmol 14:378-83. 2003
  3. ncbi A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes
    Eric B Suhler
    Uveitis and Retina Divisions, Casey Eye Institute, 3375 SW Terwilliger Blvd, Portland, OR 97239, USA
    Arch Ophthalmol 123:903-12. 2005
  4. ncbi Genotype analysis of polymorphisms in autoimmune susceptibility genes, CTLA-4 and PTPN22, in an acute anterior uveitis cohort
    Tammy M Martin
    Oregon Health and Science University, Portland, OR, USA
    Mol Vis 15:208-12. 2009
  5. ncbi Characterization of serous retinal detachments in uveitis patients with optical coherence tomography
    Annamieka Simmons-Rear
    Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA
    J Ophthalmic Inflamm Infect 2:191-7. 2012
  6. ncbi Azathioprine for ocular inflammatory diseases
    Sirichai Pasadhika
    Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA
    Am J Ophthalmol 148:500-509.e2. 2009
  7. ncbi Histopathological features of conjunctival sarcoid nodules using noninvasive in vivo confocal microscopy
    Michael S Wertheim
    Casey Eye Institute, Oregon Health and Science University, 3375 SW Terwilliger Blvd, Portland, OR 97239, USA
    Arch Ophthalmol 123:274-6. 2005
  8. ncbi Uveitis in patients with autoimmune hepatitis
    Lyndell L Lim
    Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA
    Am J Ophthalmol 147:332-338.e1. 2009
  9. ncbi Biologic therapies for inflammatory eye disease
    Lyndell Lim
    Casey Eye Institute, Oregon Health and Science University, 3375 SSW Terwilliger Boulevard, Portland, Oregon 97239, USA
    Clin Experiment Ophthalmol 34:365-74. 2006
  10. ncbi The role of choroidal and retinal biopsies in the diagnosis and management of atypical presentations of uveitis
    Lyndell L Lim
    Casey Eye Institute, Oregon Health and Sciences University, Portland Oregon, USA
    Trans Am Ophthalmol Soc 103:84-91; discussion 91-2. 2005

Collaborators

Detail Information

Publications22

  1. ncbi Presumed teratoma-associated paraneoplastic retinopathy
    Eric B Suhler
    Arch Ophthalmol 121:133-7. 2003
  2. ncbi HLA-B27-associated uveitis: overview and current perspectives
    Eric B Suhler
    Casey Eye Institute, Oregon Health and Science University, and Portland VA Medical Center, Ophthalmology Service, 97239, USA
    Curr Opin Ophthalmol 14:378-83. 2003
    ....
  3. ncbi A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes
    Eric B Suhler
    Uveitis and Retina Divisions, Casey Eye Institute, 3375 SW Terwilliger Blvd, Portland, OR 97239, USA
    Arch Ophthalmol 123:903-12. 2005
    ..We conducted a prospective, open-label phase 2 clinical trial to assess the effectiveness of infliximab in treating refractory autoimmune uveitis...
  4. ncbi Genotype analysis of polymorphisms in autoimmune susceptibility genes, CTLA-4 and PTPN22, in an acute anterior uveitis cohort
    Tammy M Martin
    Oregon Health and Science University, Portland, OR, USA
    Mol Vis 15:208-12. 2009
    ..In this study we have analyzed SNPs in PTPN22 and CTLA-4 in patients with AAU...
  5. ncbi Characterization of serous retinal detachments in uveitis patients with optical coherence tomography
    Annamieka Simmons-Rear
    Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA
    J Ophthalmic Inflamm Infect 2:191-7. 2012
    ....
  6. ncbi Azathioprine for ocular inflammatory diseases
    Sirichai Pasadhika
    Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA
    Am J Ophthalmol 148:500-509.e2. 2009
    ..To evaluate treatment outcomes of azathioprine for noninfectious ocular inflammatory diseases...
  7. ncbi Histopathological features of conjunctival sarcoid nodules using noninvasive in vivo confocal microscopy
    Michael S Wertheim
    Casey Eye Institute, Oregon Health and Science University, 3375 SW Terwilliger Blvd, Portland, OR 97239, USA
    Arch Ophthalmol 123:274-6. 2005
  8. ncbi Uveitis in patients with autoimmune hepatitis
    Lyndell L Lim
    Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, USA
    Am J Ophthalmol 147:332-338.e1. 2009
    ..To report seven cases of uveitis occurring in patients with autoimmune hepatitis (AIH), raising the possibility that uveitis may be an extrahepatic feature of AIH...
  9. ncbi Biologic therapies for inflammatory eye disease
    Lyndell Lim
    Casey Eye Institute, Oregon Health and Science University, 3375 SSW Terwilliger Boulevard, Portland, Oregon 97239, USA
    Clin Experiment Ophthalmol 34:365-74. 2006
    ....
  10. ncbi The role of choroidal and retinal biopsies in the diagnosis and management of atypical presentations of uveitis
    Lyndell L Lim
    Casey Eye Institute, Oregon Health and Sciences University, Portland Oregon, USA
    Trans Am Ophthalmol Soc 103:84-91; discussion 91-2. 2005
    ..However, in patients with an inconclusive biopsy, an additional biopsy or enucleation should be considered in cases that progress or behave atypically on treatment based on the initial biopsy findings...
  11. ncbi Possible association between scleritis and lymphoma
    Lynnelle K Smith
    Casey Eye Institute, Oregon Health and Science University, 3375 SW Terwilliger Blvd, Portland, Oregon 97239-4197, USA
    Br J Ophthalmol 91:1728-9. 2007
  12. ncbi Long-term follow-up of patients treated with multiple fluocinolone acetonide implants for noninfectious uveitis
    Rebekah C Allen
    Casey Eye Institute, Oregon Health and Science University, 3375 SW Terwilliger Blvd, Portland, OR, 97239, USA
    J Ophthalmic Inflamm Infect 2:177-82. 2012
    ..To evaluate long-term outcomes in eyes undergoing exchange of fluocinolone acetonide intravitreal implants for noninfectious uveitis...
  13. ncbi Patients with retinal vasculitis rarely suffer from systemic vasculitis
    James T Rosenbaum
    Department of Ophthalmology, Oregon Health and Science University, Portland, OR 97239, USA
    Semin Arthritis Rheum 41:859-65. 2012
    ..Systemic vasculitis is often mistakenly assumed to be a common cause of retinal vasculitis. We sought to determine the relationship between retinal vasculitis and systemic vasculitis...
  14. ncbi In vivo confocal microscopy of keratic precipitates
    Michael S Wertheim
    Casey Eye Institute, Oregon Health and Science University, Portland 97201, USA
    Arch Ophthalmol 122:1773-81. 2004
    ..To evaluate the heterogeneity of keratic precipitates (KP) in varying subtypes of uveitis by in vivo confocal microscopy (IVCM)...
  15. ncbi Management of fluocinolone implant dissociation during implant exchange
    Steven Yeh
    Department of Ophthalmology, Casey Eye Institute, Oregon Health Sciences University, Portland, Oregon 97239, USA
    Arch Ophthalmol 127:1218-21. 2009
    ..Patients undergoing FA explantation or exchange should be counseled regarding this potential complication prior to surgery...
  16. ncbi Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports
    Frederick W Fraunfelder
    Casey Eye Institute, Portland, Oregon 97239, USA
    Cutan Ocul Toxicol 29:26-9. 2010
    ..To report a possible association between hepatitis B vaccine and uveitis...
  17. ncbi Toxoplasmosis retinochoroiditis and elevated intraocular pressure: a retrospective study
    Andrew C Westfall
    Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon 97201, USA
    J Glaucoma 14:3-10. 2005
    ..Medical management of IOP is usually sufficient to treat this generally transient eye pressure rise though chronic administration of eye pressure lowering drops or glaucoma surgery may be necessary in a small proportion of patients...
  18. ncbi Mycophenolate mofetil for the treatment of scleritis
    H Nida Sen
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892-1857, USA
    Ophthalmology 110:1750-5. 2003
    ....
  19. ncbi Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study
    John H Kempen
    Center for Preventive Ophthalmology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Ophthalmic Epidemiol 15:47-55. 2008
    ....
  20. ncbi Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration
    Robert B Nussenblatt
    The National Eye Institute, Laboratory of Immunology, NIH, Building 10, 10 Center Drive, Bethesda, MD, USA
    J Autoimmun 21:283-93. 2003
    ..These studies suggest that anti-IL-2 receptor blockade could be useful in the treatment of Th1-mediated autoimmune conditions...
  21. ncbi Bilateral uveitis in a patient with autoimmune lymphoproliferative syndrome
    Wee-Kiak Lim
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892-1857, USA
    Am J Ophthalmol 139:562-3. 2005
    ..The pathogenesis of uveitis in ALPS may differ from that of the systemic disease overall. Long-term follow-up is required for patients with uveitis associated with ALPS...
  22. ncbi A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease
    Ronald R Buggage
    Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892 1857, USA
    Ocul Immunol Inflamm 15:63-70. 2007
    ..To investigate the safety and efficacy of daclizumab (Zenapax, humanized anti-Tac, HAT) in controlling the ocular manifestations of Behçet's disease...